Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Optimal management of digital ulcers in systemic sclerosis

Authors Abraham S, Steen V

Received 10 February 2015

Accepted for publication 15 April 2015

Published 15 June 2015 Volume 2015:11 Pages 939—947


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Editor who approved publication: Professor Garry Walsh

Shawn Abraham, Virginia Steen

Division of Rheumatology, Immunology, and Allergy, MedStar Georgetown University Hospital, Washington, DC, USA

Abstract: Raynaud’s phenomenon and digital ulcerations are two common clinical features seen in patients with systemic sclerosis. They are painful and lead to significant morbidity and altered hand function within this patient population. While currently there are no US Food and Drug Administration (FDA)-approved medications for the treatment of digital ulcerations in the United States, clinical trials have supported the use of pharmacologic and nonpharmacologic modalities in facilitating healing of existing digital ulcers and preventing formation of new ulcers. This article reviews the published data on these therapeutic options.

Keywords: scleroderma, systemic sclerosis, Raynaud’s phenomenon, digital ulcers, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]